Dr. Zhenrong Guo is the senior vice president of Zhejiang Jiuzhou Pharmaceutical Co., Ltd. and president of CDMO Division. He previously served as vice president at Sundia MediTech Company, Ltd. He was a senior researcher investigator and research project manager at Bristol-Myers Squibb. He most recently served as vice president at Apeloa pharmaceutical Co. and executive vice president at Zhejiang Apeloa Kangyu Pharmaceutical Co., Ltd.

Dr. Guo is currently serving as the experts for the Ministry of Science and Technology and the Science and Technology Department of Zhejiang Province. He is also serving as the review experts for the National "13th Five-Year Plan of Science and Technology Major Project for New Drug Creation" and National "13th five-Year Plan" Major Projects for Precision Medicine.

Dr. Guo has engaged in pharmaceutical R&D, GMP manufacturing, product quality, and regulatory filing for more than 25 years including Phase I to III for new drug development and NDA for new drug launch. Dr. Guo has published over 50 papers and patents in US and China. His research interests focus on anti-tumor, diabetes and Alzheimer's disease. While at Bristol-Myers Squibb, Dr. Guo made significant contributions for 2 new drugs launched in US and worldwide in 2007 and 2012, respectively. Dr. Guo has extensive experience in FDA, EU, WHO, and CFDA regulatory affairs and hand-on experience on handling FDA, EU, WHO, Japan PMDA, and Chinese FDA authorities on-site inspections.

Dr. Guo received his Ph.D. from The University of Western Ontario, MBA from Fairleigh Dickinson University, and postdoctoral fellows from University of California at Berkeley and Monell Chemical Senses Center.